Patents by Inventor Max Born

Max Born has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Anhydrate-free polymorphically pure micronized crystalline brexpiprazole di-hydrate for use in intramuscular injectable sustained release formulations
    Patent number: 10501450
    Abstract: The present invention relates to a brexpiprazole dihydrate crystalline form having a particle size distribution of d50 of at most 10 ?m and less than 5% w/w of brexpiprazole anhydrate. The present invention also relates to a process for preparing this brexpiprazole dihydrate crystalline form and to pharmaceutical compositions thereof. The present invention also relates to a process for determining the absence of brexpiprazole anhydrate in this brexpiprazole dihydrate crystalline form. This brexpiprazole dihydrate crystalline form is used for the preparation of pharmaceutical compositions having delayed release properties upon intramuscular injection.
    Type: Grant
    Filed: January 31, 2017
    Date of Patent: December 10, 2019
    Assignee: Hexal AG
    Inventors: Max Born, Christoph Langes, Hannes Lengauer
  • Anhydrate-Free Polymorphically Pure Micronized Crystalline Brexpiprazole Di-Hydrate For Use In Intramuscular Injectable Sustained Release Formulations
    Publication number: 20190047994
    Abstract: The present invention relates to a brexpiprazole dihydrate crystalline form having a particle size distribution of d50 of at most 10 ?m and less than 5% w/w of brexpiprazole anhydrate. The present invention also relates to a process for preparing this brexpiprazole dihydrate crystalline form and to pharmaceutical compositions thereof. The present invention also relates to a process for determining the absence of brexpiprazole anhydrate in this brexpiprazole dihydrate crystalline form. This brexpiprazole dihydrate crystalline form is used for the preparation of pharmaceutical compositions having delayed release properties upon intramuscular injection.
    Type: Application
    Filed: January 31, 2017
    Publication date: February 14, 2019
    Applicant: Hexal AG
    Inventors: Max BORN, Christoph LANGES, Hannes LENGAUER
  • ORAL FILMS COMPRISING 7-[4-[4-(2,3-DICHLOROPHENYL) PIPERAZIN-1-L]BUTOXY]-3,4-DIHYDRO-1H-QUINOLIN-2-ONE BASE OR SALTS OR HYDRATES THEREOF
    Publication number: 20120149713
    Abstract: An oral film comprising 7-[4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butoxy]-3,4-dihydro-1H-quinolin-2-one base or salts or hydrates thereof.
    Type: Application
    Filed: March 25, 2010
    Publication date: June 14, 2012
    Applicant: HEXAL AG
    Inventors: Andreas Krekeler, Nicole Buggele, Max Born, Sigrid Grundsteiner